A Phase I study on ACI-24, a vaccine for Alzheimer's disease being developed by AC Immune, will use PET tracer candidate florbetaben from Bayer Schering Pharma to image beta-amyloid accumulation in patients' brains. "The adoption of a diagnostic imaging substance visualizing the deposition of beta-amyloid that is targeted by our vaccine can be an important parameter for dose selection, and will provide useful complementary data," AC Immune CEO Andrea Pfeifer said.

Related Summaries